$0.535
+0.366 (+68.35%)At close
ESLA Comparative Benchmarking
In the context of the broader market, ESLA competes directly with industry leaders such as BNGO and JSPR. With a market capitalization of $23.28M, it holds a leading position in the sector. When comparing efficiency, ESLA's gross margin of N/A stands against BNGO's 52.80% and JSPR's N/A. Such benchmarking helps identify whether Estrella Immunopharma Inc is trading at a premium or discount relative to its financial performance.
Estrella Immunopharma Inc Financial Performance
The company has reported continuous net losses, with the latest net income for Q2 2026 at -2,306,339 USD. The current ratio is low at 0.20, indicating potential liquidity issues.
Financials
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.